Advanced Diabetes Care Reaches More Patients with Exclusive Distribution Agreement
A significant step forward in diabetes management was announced with an exclusive distribution agreement between A. Menarini Diagnostics and Sinocare. This collaboration grants A. Menarini Diagnostics the exclusive rights to market and distribute Sinocare’s groundbreaking third-generation continuous glucose monitoring (CGM) system in over 20 European countries.
“The partnership with A. Menarini Diagnostics is a significant milestone in our commitment to making our 3rd generation CGM systems widely accessible to people with diabetes,” said Dr. Jiangfeng Fei, Head of CGM Business Unit, Sinocare. “We are pleased to enter into a strategic partnership with A. Menarini Diagnostics, a leader in the healthcare industry, to bring this innovative diabetes technology to a broader audience.”
This strategic alliance is poised to make a real difference in the lives of individuals living with diabetes.
Sinocare’s third-generation CGM system is designed for accurate and continuous blood glucose measurement. This technology provides invaluable data, empowering people with diabetes and their healthcare providers to make more informed decisions about managing their condition.
“Securing the exclusive rights to distribute and market the 3rd Generation Sinocare CGM System in various countries is in line with our commitment to providing innovative healthcare solutions,” comments Fabio Piazzalunga, General Manager and Global Head of A. Menarini Diagnostics. “We are confident that this long-term partnership will meet the growing demand for advanced diabetes care.”
Through its extensive network, A. Menarini Diagnostics is committed to ensuring that Sinocare’s cutting-edge CGM technology reaches individuals who can benefit most from it. The company’s broad expertise and resources will play a crucial role in expanding the availability of this breakthrough technology.
A. Menarini Diagnostics: Committed to Improving Global Health Outcomes
A. Menarini Diagnostics has established itself as a true leader in the healthcare industry, dedicated to developing and delivering innovative solutions that improve health outcomes worldwide. For over 45 years, the company has been a trusted partner to healthcare professionals, providing them with the tools and technology they need to make safe and sustainable diagnoses.
As part of the Menarini Pharmaceutical Group, founded in 1886, A. Menarini Diagnostics operates in over 140 countries, employing more than 17,000 dedicated individuals.
The company’s commitment is exemplified by its ambitious goal: achieving sales of 4.375 billion euros in 2023.
Sinocare: Leading the Way in Biosensing Innovation
Sinocare, recognized as the largest manufacturer of blood glucose meters in Asia, has a strong track record of innovation in biosensing solutions. Founded in 2002, Sinocare made history as the first blood glucose meter company in China to go public. Since then, the company has expanded its global footprint across Asia, Europe, and North America, forging strategic partnerships and acquiring companies such as US-based PTS Diagnostics Inc. and Nipro Diagnostic Inc. (now Trividia Health Inc.).
This commitment to innovation has propelled Sinocare to become the world’s fourth largest manufacturer of blood glucose meters and a leading player in the point-of-care testing (POCT) arena.
What are the key features and benefits of Sinocare’s 3rd generation CGM system?
## Bringing Advanced Diabetes Care to Europe: An Interview with Menarini Diagnostics
**Interviewer:** We’re discussing an exciting development in diabetes care today. A. Menarini Diagnostics and Sinocare have just announced an exclusive distribution agreement that will bring Sinocare’s 3rd generation Continuous Glucose Monitoring (CGM) system to over 20 European countries. Joining us to shed light on this partnership is [Name of Alex Reed], [Alex Reed Title at Menarini Diagnostics]. Welcome!
**Alex Reed:** Thank you for having me.
**Interviewer:** This collaboration seems like a significant step forward for diabetic patients in Europe. Could you tell us more about this new CGM system and what sets it apart?
**Alex Reed:** Absolutely. Sinocare’s 3rd generation CGM system is designed to provide incredibly accurate and continuous blood glucose readings. This constant stream of data is invaluable for both patients and their healthcare providers. It allows for a much more nuanced understanding of individual glucose patterns, leading to better-informed decisions about treatment and lifestyle adjustments.
**Interviewer:** Accessibility is a major challenge in healthcare. How will this partnership improve access to this vital technology for people with diabetes?
**Alex Reed:** This agreement is truly about expanding access. Sinocare has developed groundbreaking technology, and Menarini Diagnostics has a vast and established network across Europe. By combining our strengths, we can ensure this innovative CGM system reaches a much broader audience of people who can benefit from it.
**Interviewer:** Dr. Jiangfeng Fei, Head of CGM Business Unit at Sinocare, emphasized a commitment to making their technology widely accessible. How does this align with Menarini Diagnostics’ mission?
**Alex Reed:** Our mission at Menarini Diagnostics is to provide innovative healthcare solutions that improve patient care. This partnership perfectly embodies that mission. We are dedicated to bringing cutting-edge technology like Sinocare’s CGM system to patients who need it, ultimately empowering them to better manage their health.
**Interviewer:** It sounds like this is a promising partnership with the potential to make a real difference.
**Alex Reed:** We’re incredibly excited about the possibilities. We believe this collaboration can pave the way for more individuals with diabetes in Europe to live healthier, more fulfilling lives.
**Interviewer:** Thank you, [Name of Alex Reed], for sharing your insights and for your commitment to improving diabetes care.
**Alex Reed:** Thank you.
